ADAG Key Statistics, Chart & Performance
The current stock price of ADAG is 1.53 USD. In the past month the price decreased by -15.47%. In the past year, price decreased by -20.93%.
ADAG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About ADAG
Company Profile
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 138 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Company Info
ADAGENE INC-ADR
4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park
Suzhou JIANGSU 215123 CN
CEO: Peter (Peizhi) Luo
Employees: 138
Phone: 8651287773632
ADAGENE INC-ADR / ADAG FAQ
What does ADAG do?
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 138 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
What is the current price of ADAG stock?
The current stock price of ADAG is 1.53 USD. The price decreased by -7.27% in the last trading session.
Does ADAG stock pay dividends?
ADAG does not pay a dividend.
What is the ChartMill rating of ADAGENE INC-ADR stock?
ADAG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of ADAG stock?
ADAGENE INC-ADR (ADAG) has a market capitalization of 72.08M USD. This makes ADAG a Micro Cap stock.
Can you provide the ownership details for ADAG stock?
You can find the ownership structure of ADAGENE INC-ADR (ADAG) on the Ownership tab.
Can you provide the short interest for ADAG stock?
The outstanding short interest for ADAGENE INC-ADR (ADAG) is 0.05% of its float.
ADAG Technical Analysis
ADAG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADAG. ADAG may be in some trouble as it scores bad on both profitability and health.
ADAG Financial Highlights
Over the last trailing twelve months ADAG reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS increased by 10.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.94% | ||
| ROE | -78.84% | ||
| Debt/Equity | 0.06 |
ADAG Forecast & Estimates
14 analysts have analysed ADAG and the average price target is 9.41 USD. This implies a price increase of 514.95% is expected in the next year compared to the current price of 1.53.
For the next year, analysts expect an EPS growth of 17.26% and a revenue growth -22.52% for ADAG